PE20040314A1 - Formulacion superfina de salmeterol - Google Patents

Formulacion superfina de salmeterol

Info

Publication number
PE20040314A1
PE20040314A1 PE2003000624A PE2003000624A PE20040314A1 PE 20040314 A1 PE20040314 A1 PE 20040314A1 PE 2003000624 A PE2003000624 A PE 2003000624A PE 2003000624 A PE2003000624 A PE 2003000624A PE 20040314 A1 PE20040314 A1 PE 20040314A1
Authority
PE
Peru
Prior art keywords
formulation
solution
propellant
salmeterol
water
Prior art date
Application number
PE2003000624A
Other languages
English (en)
Inventor
Tanya Kathleen Church
David Andrew Lewis
Brian John Meakin
Gaetano Brambilla
David Ganderton
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32087950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20040314(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of PE20040314A1 publication Critical patent/PE20040314A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

QUE COMPRENDE: 1)UN INGREDIENTE ACTIVO SELECCIONADO DE: SALMETEROL O UN ESTEREOISOMERO; 2)SAL ACEPTABLE PARA USO FISIOLOGICO O SOLVATO DEL MISMO, DISUELTO EN UN SISTEMA PROPELENTE QUE ESTA CONFORMADO POR: i)UN PROPELENTE HFA LICUADO; ii)UNA CANTIDAD NO MAYOR A 35% p/p, DEL PESO TOTAL DE LA FORMULACION, DE UN CO-SOLVENTE, EL CUAL SE SELECCIONA DE ENTRE: ALCOHOLES ALQUILICOS INFERIORES (C1-C4), POLIOLES, POLIALQUILENGLICOLES, (POLI)ALCOXI DERIVADOS Y SUS COMBINACIONES; Y, iii)ENTRE 0% Y 5% p/p DE AGUA. LA PRESENTE FORMULACION SE ADMINISTRA POR MEDIO DE INHALADORES DOSIFICADORES PRESURIZADOS, CARACTERIZADA PORQUE PERMITE UNA PROFUNDA PENETRACION PULMONAR Y PORQUE PROVEE UNA FRACCION DE PARTICULAS MENORES O IGUALES DE 1,1 µm (FRACCION SUPER DELGADA) EN UNA CANTIDAD 30% MAYOR QUE LAS CONVENCIONALES. SE REFIERE TAMBIEN A UN METODO PARA PREPARAR LA FORMULACION DESCRITA, QUE COMPRENDE: 1)PREPARAR UNA SOLUCION DE UNO O MAS INGREDIENTES ACTIVOS; 2)OPCIONALMENTE AGREGAR UNA CANTIDAD DE AGUA Y AJUSTAR EL pH DE LA SOLUCION; 3)RELLENAR EL DISPOSITIVO CON DICHA SOLUCION; 4)APLICAR VALVULAS Y GASIFICAR; 5)AGREGAR UN PROPELENTE QUE CONTIENE UN HFA
PE2003000624A 2002-10-23 2003-06-20 Formulacion superfina de salmeterol PE20040314A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02023589A EP1415647A1 (en) 2002-10-23 2002-10-23 "Long-acting beta-2 agonists ultrafine formulations"

Publications (1)

Publication Number Publication Date
PE20040314A1 true PE20040314A1 (es) 2004-07-05

Family

ID=32087950

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000624A PE20040314A1 (es) 2002-10-23 2003-06-20 Formulacion superfina de salmeterol

Country Status (12)

Country Link
US (1) US8088362B2 (es)
EP (2) EP1415647A1 (es)
AR (1) AR040450A1 (es)
AT (1) ATE421875T1 (es)
AU (1) AU2003245965A1 (es)
BR (1) BR0306663A (es)
CA (1) CA2503183C (es)
DE (1) DE60326053D1 (es)
ES (1) ES2319887T3 (es)
NO (1) NO20051956L (es)
PE (1) PE20040314A1 (es)
WO (1) WO2004037227A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
SI1273292T1 (en) * 2001-07-02 2004-12-31 Chiesi Farmaceutici S.P.A. Optimised formulation of tobramycin for aerosolization
EP1415647A1 (en) 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
WO2008057248A2 (en) * 2006-10-26 2008-05-15 Next Breath Llc Phospholipid-based inhalation system
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP3311820A1 (en) * 2008-02-26 2018-04-25 Sunovion Respiratory Development Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2440196A4 (en) * 2009-06-09 2013-01-02 Elevation Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC
EP2593108A2 (en) * 2010-07-16 2013-05-22 Cilpa Limited Pharmaceutical compositions comprising r(+) budesonide and one or more bronchodilators
WO2021216779A1 (en) * 2020-04-21 2021-10-28 Amphastar Pharmaceuticals, Inc. Anti-viral pharmaceutical formulations administered via devices for lung targeted delivery

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
CZ288146B6 (en) * 1994-12-22 2001-05-16 Astra Ab Pharmaceutical aerosol preparation, process of its preparation and use
PL180895B1 (pl) * 1995-04-14 2001-04-30 Glaxo Wellcome Inc Inhalator z dozymetrem
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6423298B2 (en) * 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
EP1100465B1 (de) * 1998-07-24 2004-11-24 Jago Research Ag Medizinische aerosolformulierungen
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US20050048001A1 (en) * 1999-11-23 2005-03-03 Cripps Alan Leslie Pharmaceutical formulations of salmeterol
ES2238334T3 (es) * 1999-12-24 2005-09-01 Glaxo Group Limited Formulacion farmaceutica en aerosol de salmeterol y propionato de fluticasona.
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0009773D0 (en) * 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
ME00220B (me) * 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
SE0004750D0 (sv) * 2000-12-19 2000-12-19 Astrazeneca Ab Novel formulation
US20020189610A1 (en) * 2001-02-01 2002-12-19 Karl-Heinz Bozung Pharmaceutical compositions containing an ipratropium salt and a betamimetic
US6455028B1 (en) * 2001-04-23 2002-09-24 Pharmascience Ipratropium formulation for pulmonary inhalation
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
EP1415647A1 (en) 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
ME00077B (me) * 2002-03-01 2010-06-10 Chiesi Farm Spa Formoterol najfiniji preparat
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Also Published As

Publication number Publication date
AU2003245965A1 (en) 2004-05-13
US8088362B2 (en) 2012-01-03
EP1553922B1 (en) 2009-01-28
EP1553922A1 (en) 2005-07-20
WO2004037227A1 (en) 2004-05-06
US20060120966A1 (en) 2006-06-08
EP1415647A1 (en) 2004-05-06
BR0306663A (pt) 2004-10-19
CA2503183A1 (en) 2004-05-06
ES2319887T3 (es) 2009-05-14
NO20051956D0 (no) 2005-04-21
ATE421875T1 (de) 2009-02-15
NO20051956L (no) 2005-07-22
DE60326053D1 (de) 2009-03-19
AR040450A1 (es) 2005-04-06
CA2503183C (en) 2011-06-14

Similar Documents

Publication Publication Date Title
PE20040314A1 (es) Formulacion superfina de salmeterol
PE20030824A1 (es) Formulacion superfina de formoterol
AR101593A2 (es) Formulación superfina de formoterol
JP5612578B2 (ja) チオール化抗酸化物質を含む脂質製剤
CN102008728B (zh) 液体贮库制剂
AR052198A1 (es) Formulaciones anticuerpo anti a beta
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
AR064826A1 (es) Formulaciones de anticuerpos anti-il-13 y usos de los mismos. dispositivos, parche y jeringa
AR052545A1 (es) Suspension no acuosa inyectable
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
CO6361907A2 (es) Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo
WO2007084247A3 (en) Stable therapeutic formulations
SG156624A1 (en) Organo-gel formulations for therapeutic applications
WO2006081279A3 (en) Control of drug release by transient modification of local microenvironments
WO2009029958A3 (en) Implantable delivery device
AR065039A1 (es) Una composicion farmaceutica de liberacion modificada, un proceso para su preparacion, un metodo para su utilizacion y su uso
PE20070377A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
PE20070437A1 (es) FORMULACION ACUOSA hFSH
RU2011117331A (ru) Имплантируемое устройство для доставки рисперидона и способы его применения
AR095114A1 (es) Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina
PE20080204A1 (es) Formulaciones farmaceuticas que comprenden un anticolinergico y un beta agonista
AR054844A1 (es) Vacuna contra lawsonia y metodos de uso de la misma
PE20030519A1 (es) Forma de dosificacion, dispositivo y metodos de tratamiento
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
AR081187A1 (es) Formulaciones inyectables parasiticidas de levamisol y lactonas macrociclicas. metodo de preparacion. metodo de tratamiento.

Legal Events

Date Code Title Description
FC Refusal